ARTICLE | Clinical News
Cellcor regulatory update
July 18, 1994 7:00 AM UTC
The FDA granted Orphan Drug designation to the Newton, Mass., company's autolymphocyte therapy (ALT) to treat renal cell carcinoma. The cellular therapy is in a Phase III trial in advanced kidney canc...